|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
SundayMerck Serono - Press Release: REBIF
Merck Serono - Press Release: REBIF
MERCK SERONO IS LAUNCHED Geneva, Switzerland, January 8, 2007 - Following the successful closing of the Share Purchase Agreement (SPA) and the resolutions passed during the Extraordinary General Meeting of Serono S.A.1, Merck KGaA today announced the official launch of Merck Serono S.A. (virt-x: SEO and NYSE:SRA). “With the combined innovative power of two strong companies, we have the unique opportunity to create a superb union of pharmaceutical chemistry and biotechnology,” said Elmar Schnee, new Chief Executive Officer of Merck Serono S.A.. “We want to utilize the best of both companies. A total of 28 projects in clinical development, a combined R&D budget of approximately EUR 1 billion and the two key growth drivers Erbitux® for oncology and Rebif® for the treatment of multiple sclerosis, give us the best foundations for a successful future.”Merck Serono - CLICK FOR MORE |